Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.

ABSTRACT:

Objectives

To perform a systematic review and network meta-analysis to compare the efficacy and safety of currently available treatments for the management of metastatic hormone-sensitive prostate cancer (mHSPC), as there has been a paradigm shift with the use of next-generation androgen receptor inhibitors (ARIs) and docetaxel.

Methods

Multiple databases were searched for articles published before May 2020 according to the Preferred Reporting Items for Systematic Review and Meta-analysis extension statement for network meta-analysis. Studies comparing overall/progression-free survival (OS/PFS) and/or adverse events (AEs) in patients with mHSPC were eligible.

Results

Nine studies (N = 9960) were selected, and formal network meta-analyses were conducted. Abiraterone (h

SUBMITTER: Mori K 

PROVIDER: S-EPMC9291853 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature